111in-bu-12
mAbexperimentalImaging agent
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2008 (NCT00643240)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD19Radiodepletion
CD19 radiodepletion
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 111-indium
Oral
No
Parenteral
No
Topical
No
Also known as
- 111in-bu-12
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00643240 | Phase 1 | Jan 1, 2008 | University of Minnesota |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Minnesota | Academic/Hospital | 1 | 1 | 1 | 2008 |
1 organizations
Page 1 / 1